相关临床试验
16
2 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
1996
已完成
10
62.5%
尚未招募
2
12.5%
招募中
4
25.0%
暂无批准数据
- Researchers at Hokkaido University developed e-MITO, a surface engineering approach that coats isolated mitochondria with PEG and cell-penetrating peptides to enhance stability and cellular uptake. - In laboratory experiments, CPP–PEG-engineered mitochondria were taken up more efficiently by cells than unmodified mitochondria and led to increased mitochondrial respiratory activity in recipient cells. - The modular design could enable mitochondria to be targeted to specific diseases or tissues, representing an early step toward using organelles as therapeutic tools. - The study, led by Professor Yuma Yamada, was published in Advanced Materials Interfaces and supported by JST FOREST Program and AMED.
- FELIQS Corporation completed a $9 million Series A funding round co-led by a major American pharmaceutical company and Beyond Next Ventures to advance FLQ-101 for retinopathy of prematurity prevention. - FLQ-101 is a first-in-class small molecule targeting oxidized lipids that can be administered once daily orally or intravenously to enhance physiological retinal vascularization. - The FDA has granted FLQ-101 both Fast Track and Orphan Drug designations, with the Phase 1b/2 tROPhy-1 study scheduled to begin in summer 2025. - The funding will support expansion of operational and clinical development teams while accelerating key milestones in the U.S. clinical program for this underserved pediatric population.
- Alpha Fusion and Curadh MTR announced a strategic partnership including a joint venture to advance global development of Astatine-211 based radiopharmaceuticals for cancer therapy. - The collaboration combines Alpha Fusion's At-211 drug discovery platform and early clinical work in Japan with Curadh's global radiopharmaceutical development expertise. - The joint venture will focus on clinical development of lead products in the US while building a broader pipeline of At-211 products using cyclotron production and GMP manufacturing. - Astatine-211's unique properties as a halogen emitter with short half-life position it as one of the most promising alpha particles for molecularly targeted cancer therapy.
